Now Available:
Download the podcast of Dr. Sobell's presentation

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

MSK Video Report:


Dr. Jeffrey M. Sobell presents "Long-Term Management of Patients with Psoriasis" from our 5-part series, "Practical Approaches to Solving Psoriasis Challenges"

Arthritis: S. pyogenes-Linked New-Onset Childhood Arthritis Differs in Severity, Duration, from Other Types
Up to 35% of children with new-onset arthritis test positive for S. pyogenes and have a different disease course than children with other forms of inflammatory arthritis; they do not need routine cardiology follow-up, according to a population-based study...

Arthritis: Nothing Fishy: Fish Oil Supplement Reduces NSAID Need in RA
Rheumatoid arthritis patients who take fish oil supplements can slash their need for NSAIDs...

Consumer News: Pain as an Art Form
Frustrated by the inadequacy of words, chronic pain sufferers often turn to art to illustrate the pain they feel...

BioPharm Business: UCB's Cimzia Approved in the US for the Treatment of Moderate-to-Severe Crohn's Disease; Dosed Subcutaneously Every 4 Weeks
The US FDA has approved Cimzia (certolizumab pegol), indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate-to-severe active disease who have an inadequate response to conventional therapy...

BioPharm Business: GSK, Regulus Form Alliance to Develop microRNA-Targeted Therapeutics to Treat RA and IBD; Deal Potentially Valued at Over $600 Million
GlaxoSmithKline and Regulus Therapeutics LLC announced a worldwide strategic alliance to discover, develop, and market novel microRNA(miRNA)-targeted therapeutics to treat inflammatory diseases such as RA and inflammatory bowel disease...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .